1.20
-6.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dogwood Therapeutics
From its filings with the US Securities and Exchange Commission
Dogwood Therapeutics is based in Alpharetta, Georgia and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DWTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $34.3m. At that date it held total assets of $90.2m and shareholders' equity of $74.9m.
We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Following the closing of the Combination described below, we became the sole owner of Pharmagesic (Holdings) Inc. (“Pharmagesic”) and their wholly owned subsidiary, Wex Pharmaceuticals, Inc. (“Wex”), and Wex’s wholly owned subsidiaries, IWT Bio, Inc. (“IWT”), Wex Medical Corporation (“WMC”), and Wex Medical Limited (“WML”).
Our pipeline is focused on treating chronic neuropathic pain and neuropathy. Our Halneuron® Nav1.7 modulation program is intended to treat chronic and acute pain disorders. Our recently licensed SP16 program is centered on a cell signaling molecule that has shown early promise in treating neuropathy and nerve damage. The Halneuron® program is a proprietary non-opioid Nav1.7 analgesic program centered on voltage-gated sodium channel modulation, a mechanism known to be effective for reducing pain. SP16 is the focus of a planned Phase 1b study that is fully funded through a research grant supplied by the National Cancer Institute, with patient enrollment projected to start in mid-2026.
Quoted from its 10-K, filed 18 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Dec 2020
- Employees
- 4
- Website
- virios.com ↗
- Head office
- 44 MILTON AVENUE, ALPHARETTA, GA, 30009
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Gregory DuncanChairman of the Board, Chief Executive Officer, since 2018$881,220
- Ms. Angela WalshChief Financial Officer$364,328
- Mr. Ralph GrosswaldSenior Vice President - Operations$425,027
- Dr. R. Michael GendreauChief Medical Officer$511,616
- Dr. Melvin TohDirector
- Mr. Alan YuDirector
- Dr. Abel De La RosaIndependent Director$46,308
- Mr. David KeeferIndependent Director$55,082
- Mr. John ThomasIndependent Director$48,746
- Dr. Richard WhitleyIndependent Director$46,796
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IMC-1 is a proprietary fixed dose combination of famciclovir and celecoxib.
- The firm employs four full-time staff members in the US market.
- IMC-2 targets Epstein-Barr virus and other herpesviruses with specific activity.
Weaknesses
- The company has only four employees to manage its pipeline.
- Operations are concentrated in Alpharetta, Georgia, limiting geographic diversity.
- Listing occurred on 17 December 2020, indicating a relatively recent market entry.
Opportunities
- Novel antiviral therapies address diseases like fibromyalgia and Long-COVID.
- Dual mechanism therapy aims to suppress herpes virus activation synergistically.
- Converting activated herpesvirus to dormancy offers new treatment pathways.
Threats
- Viral triggered abnormal immune responses present complex treatment challenges.
- Herpesvirus activation and replication require continuous and effective suppression.
- Long-COVID and fibromyalgia conditions involve significant patient burden.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.